🇺🇸 FDA
Pipeline program

TD-1607

0098

Phase 1 small_molecule completed

Quick answer

TD-1607 for Serious Infections Due to Known or Suspected Gram-positive Pathogens is a Phase 1 program (small_molecule) at Theravance Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Theravance Biopharma
Indication
Serious Infections Due to Known or Suspected Gram-positive Pathogens
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials